Cite
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
MLA
Mahadeo, Kris Michael, et al. “Tabelecleucel for Allogeneic Haematopoietic Stem-Cell or Solid Organ Transplant Recipients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE): A Phase 3, Multicentre, Open-Label Trial.” Lancet Oncology, vol. 25, no. 3, Mar. 2024, pp. 376–87. EBSCOhost, https://doi.org/10.1016/S1470-2045(23)00649-6.
APA
Mahadeo, K. M., Baiocchi, R., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Duan, X., Gamelin, L., Ghobadi, A., Guzman-Becerra, N., Joshi, M., Mehta, A., Navarro, W. H., Nikiforow, S., O’Reilly, R. J., Reshef, R., Ruiz, F., Spindler, T., & Prockop, S. (2024). Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. Lancet Oncology, 25(3), 376–387. https://doi.org/10.1016/S1470-2045(23)00649-6
Chicago
Mahadeo, Kris Michael, Robert Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, et al. 2024. “Tabelecleucel for Allogeneic Haematopoietic Stem-Cell or Solid Organ Transplant Recipients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE): A Phase 3, Multicentre, Open-Label Trial.” Lancet Oncology 25 (3): 376–87. doi:10.1016/S1470-2045(23)00649-6.